Novel drug candidates and therapies targeting autoimmune and inflammatory conditions advance clinical development. Abivax SA’s obefazimod, a first-in-class miRNA-enhancing oral drug for ulcerative colitis, showed statistically significant remission and safety in Phase 3 trials, propelling its stock by over 500%. Matchpoint Therapeutics partnered with Novartis on oral covalent inhibitors aimed at transcription factors implicated in inflammatory diseases. Additional approaches target osteogenesis imperfecta and rheumatoid arthritis, indicating strong pipeline activity centered on immune modulation and inflammation control in chronic disease.